Vaxcyte EVP, COO Jim Wassil sells $1.56m in shares

Jim Wassil, Executive Vice President, Chief Scientific Officer, and Chief Operating Officer at Vaxcyte, Inc. (NASDAQ:PCVX), sold 18,000 shares of the company’s common stock on October 5, 2026. The shares were sold at a price of $86.74 each, totaling $1,561,320. The stock currently trades at $71.38, reflecting a pullback from the transaction price, though shares have delivered a strong 63% return over the past year. This transaction was executed pursuant to a Rule 10b5-1 trading plan, which was adopted on December 9, 2025.

On the same day, Mr. Wassil also acquired 18,000 shares of Vaxcyte common stock through the exercise of stock options. These options were exercised at a price of $5.35 per share, amounting to a total value of $96,300. The stock option was fully vested and exercisable, with an expiration date of April 17, 2030.

Following these transactions, Jim Wassil directly holds 145,435 shares of Vaxcyte, Inc. common stock. According to InvestingPro analysis, the stock appears overvalued at current levels. Investors seeking deeper insights can access comprehensive analysis through the platform’s Pro Research Report, one of 1,400+ available for US equities.

In other recent news, Vaxcyte’s OPUS-1 trial for its VAX-31 vaccine candidate has been a focal point for several analysts. The trial met its primary endpoint, with BofA Securities raising its price target for Vaxcyte shares to $146, while maintaining a Buy rating. Guggenheim also increased its price target to $125, citing the trial’s success in achieving non-inferiority against Pfizer’s Prevnar 20 and Merck’s Capvaxive. BTIG reiterated a Buy rating with an $89 price target, noting the trial exceeded management’s predictions by meeting all 32 prespecified co-primary endpoints. However, BofA adjusted its price target slightly downward to $130 due to a revised launch timeline for VAX-31, now expected in 2029. Additionally, Vaxcyte announced new executive appointments, naming Luis Jodar as Chief Medical Officer and David McAvoy as Chief Legal Officer. The company also updated its timeline, expecting topline safety and immunogenicity data from the VAX-31 trial by the end of October 2026. These developments highlight the company’s ongoing efforts in advancing its vaccine candidate.